7-Aug-2026
AbCellera to Report Phase 2 Menopause Therapy Data
TipRanks (Fri, 7-Aug 5:19 PM ET)
AbCellera rises as it will release phase 2 results of menopause asset
Seeking Alpha News (Fri, 7-Aug 5:06 PM ET)
Business Wire (Fri, 7-Aug 4:30 PM ET)
Piper Sandler Remains a Buy on AbCellera Biologics (ABCL)
TipRanks (Fri, 7-Aug 11:28 AM ET)
AbCellera Biologics (ABCL) Gets a Buy from Cantor Fitzgerald
TipRanks (Thu, 6-Aug 8:00 AM ET)
Stifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
TipRanks (Thu, 6-Aug 7:59 AM ET)
TipRanks (Thu, 6-Aug 6:05 AM ET)
AbCellera Biologics GAAP EPS of -$0.18 misses by $0.02, revenue of $4.1M misses by $3.75M
Seeking Alpha News (Wed, 5-Aug 4:18 PM ET)
AbCellera Reports Q2 2026 Business Results
Business Wire (Wed, 5-Aug 4:05 PM ET)
Here are the major earnings after the close Wednesday
Seeking Alpha News (Wed, 5-Aug 10:00 AM ET)
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of August 7, 2026, ABCL stock price climbed to $6.93 with 5,577,195 million shares trading.
ABCL has a beta of 2.77, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.14 to the broad based SPY ETF.
ABCL has a market cap of $2.12 billion. This is considered a Mid Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $4 million in Revenue and -$.18 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.01.
In the last 3 years, ABCL traded as high as $8.44 and as low as $1.89.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IBB, CPAI, SPDW, IDNA, GWX.
ABCL has outperformed the market in the last year with a price return of +63.4% while the SPY ETF gained +23.5%. ABCL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +43.8% and +30.5%, respectively, while the SPY returned +6.0% and +4.6%, respectively.
ABCL support price is $6.17 and resistance is $6.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.